Ligand Files XOMA Financials: $886M Deal Shows $142M Goodwill, $41M H1 Loss
LGND sits 77% above its 52-week low of $161.82.
Summary
Ligand's 8-K/A provides the first detailed financials for its XOMA Royalty acquisition, revealing XOMA's $41.2M H1 loss and the $886M purchase price allocation, including $142M in goodwill.
Key Events · M&A and Partnerships · LGND
-
XOMA H1 2026 Financials Disclosed
XOMA Royalty reported a net loss of $41.2 million for the six months ended June 30, 2026, including $19.7 million in credit losses on Daré receivables and $23.6 million in impairment charges.
-
Purchase Price Allocation Revealed
Estimated net purchase consideration was $886.2 million, with preliminary goodwill of $142.4 million and identified intangible assets of $97.6 million across 8 programs.
-
Pro Forma Combined Results
Pro forma combined net income was $17.9 million for H1 2026 and $139.6 million for full-year 2025, reflecting the merger as if completed January 1, 2025.
-
Financing and Debt Repayment
The acquisition was funded with $700 million in 0% convertible notes issued June 25, 2026, plus cash; Ligand repaid XOMA's $114.6 million Blue Owl loan and redeemed $68.6 million in preferred stock.
Analysis · LGND · Life Sciences
This amendment delivers the first hard look at XOMA Royalty's standalone financials and the combined pro forma picture since the July 14 merger closed. XOMA lost $41.2 million in the first half of 2026, driven by a $19.7 million write-off of Daré receivables and $23.6 million in impairment charges tied to failed clinical programs. Ligand paid an estimated $886 million in net consideration, booking $142 million in goodwill and $97.6 million in identified intangible assets. The pro forma statements show the combined company would have earned $17.9 million in H1 2026 and $139.6 million in 2025, giving investors their first concrete view of the deal's earnings impact.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LGND was trading at $286.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $161.82 to $326.63. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.